Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.66 |
| ▸ | PRKCA | P17252 | 2/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.52 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15602 | 1.00 | DGKA (0.66) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL15664644 | 1.00 | DGKA (0.66) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL4440862 | 0.99 | DGKA (0.64) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL154132 | 0.96 | FAAH (0.62) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Propene SCHEMBL22734258 | 0.95 | DGKA (0.60) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Sulfuric Acid SCHEMBL2121079 | 0.95 | DGKA (0.60) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Stearic Acid SCHEMBL8852762 | 0.92 | FABP3 (0.60) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Glyceryl Monooleate SCHEMBL10792697 | 0.91 | DGKA (0.83) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| Glyceryl Monooleate SCHEMBL19003096 | 0.91 | DGKA (0.83) | DGKAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL16041 | 0.91 | LMNA (0.60) | DGKAPRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140044786-A1 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE | ZYSIS LIMITED (GB) | 2014-02-13 | — | — | US | claimed |
| US-8242165-B2 | Mucoadhesive nanoparticles for cancer treatment | CREIGHTON UNIVERSITY (US) | 2012-08-14 | — | — | US | claimed |
| WO-2011050388-A1 | LIQUID CRYSTAL COMPOSITION AND METHOD OF USE | MONASH UNIVERSITY (AU) | 2011-05-05 | — | — | WO | claimed |
| US-20100323977-A9 | Mucoadhesive nanoparticles for cancer treatment | US ARMY, SECRETARY OF THE ARMY | 2010-12-23 | — | — | US | claimed |
| US-20090275526-A1 | Mucoadhesive nanoparticles for cancer treatment | DASH ALEKHA K | 2009-11-05 | — | — | US | claimed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | TRIS PHARMA INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12569508-B2 | Antimicrobial compositions and methods of use | UNIV SOUTH AUSTRALIA (AU) | 2026-03-10 | — | — | US | disclosed |
| US-12521342-B2 | Fast disintegrating tablet | CUBOPHARM PTY LTD (AU) | 2026-01-13 | — | — | US | disclosed |
| US-12521350-B2 | Liquid crystalline dosage form for administering a statin | CUBOPHARM PTY LTD (AU) | 2026-01-13 | — | — | US | disclosed |
| US-12514818-B2 | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system | TRIS PHARMA, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | MELBOURNE INST TECH (AU) | 2025-11-06 | — | — | US | disclosed |
| WO-2013032207-A1 | SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF PHARMACOLOGICALLY ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012168484-A1 | TARGETS AND AGENTS FOR THE TREATMENT OF IMPAIRED BONE FRACTURE HEALING | Université Libre de Bruxelles (BE) | 2012-12-13 | — | — | WO | disclosed |
| US-8242165-B2 | Mucoadhesive nanoparticles for cancer treatment | CREIGHTON UNIVERSITY (US) | 2012-08-14 | — | — | US | disclosed |
| WO-2011050388-A1 | LIQUID CRYSTAL COMPOSITION AND METHOD OF USE | MONASH UNIVERSITY (AU) | 2011-05-05 | — | — | WO | disclosed |
| US-20100323977-A9 | Mucoadhesive nanoparticles for cancer treatment | US ARMY, SECRETARY OF THE ARMY | 2010-12-23 | — | — | US | disclosed |
| US-20070108405-A1 | Compositions and methods for delivery of biologically active agents | FH FAULDING & CO., LTD. (AU) | 2007-05-17 | — | — | US | disclosed |
| EP-1667656-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | FH Faulding & Co. Limited (AU) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005021046-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | FH FAULDING & CO LTD (AU) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275526-A1 | Mucoadhesive nanoparticles for cancer treatment | PNLIP, MUC1, LIPA | DGKA 146/4885PRKCA 1379/4885PRKCE 1783/4885 |
| US-12569508-B2 | Antimicrobial compositions and methods of use | PCTP, PYCARD, PLIN3 | DGKA 1890/4885PRKCA 1881/4885PRKCE 1886/4885 |
| US-20140044786-A1 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE | CYP2A6, CYP2C19, CYP2D6 | DGKA 3386/4885PRKCA 3275/4885PRKCE 3167/4885 |
| US-20260096986-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A FLOATING INTERPENETRATING POLYMER NETWORK FORMING SYSTEM | SI, FABP2, FABP6 | DGKA 1362/4885PRKCA 2578/4885PRKCE 2770/4885 |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | DGKA 1543/4885PRKCA 657/4885PRKCE 474/4885 |
| US-20100323977-A9 | Mucoadhesive nanoparticles for cancer treatment | PNLIP, MUC1, LIPA | DGKA 146/4885PRKCA 1379/4885PRKCE 1783/4885 |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | CD47, LY96, TSG101 | DGKA 826/4885PRKCA 2423/4885PRKCE 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.